info@zanaxhealth.com +91 79 4890 2200 Mon to Sat, 9:30 AM to 6:30 PM IST
WHO-GMP Certified Partner Network
Regulatory Affairs

WHO-GMP vs EU-GMP: What Pharma Exporters Need to Know

WHO-GMP vs EU-GMP: What Pharma Exporters Need to Know

For Indian pharmaceutical companies looking at export markets, Good Manufacturing Practice certification is the first question every buyer asks. Two of the most common frameworks are WHO-GMP and EU-GMP. Both set out how medicines should be produced and controlled, yet the markets they unlock and the investment they require are quite different.

What WHO-GMP Covers

WHO-GMP guidelines are published by the World Health Organization and are widely accepted across Africa, Southeast Asia, Latin America and CIS countries. In India, WHO-GMP certification is issued under the WHO certification scheme through the national and state regulators. It is often the minimum expectation for tender supply and product registration in emerging markets.

  • Recognised by many ministries of health and procurement agencies
  • Focus on documentation, quality control and hygiene
  • Achievable for most well run facilities with targeted upgrades

What EU-GMP Adds

EU-GMP is the standard enforced by European regulators and is aligned with PIC/S. It places much greater emphasis on facility design, data integrity, validation and a mature pharmaceutical quality system. Sites that pass an EU inspection are often viewed favourably by regulators in other highly regulated markets as well.

EU-GMP is less a certificate and more a culture. Facilities that succeed treat it as a continuous way of working rather than a one time audit.

Key Differences at a Glance

Area WHO-GMP EU-GMP
Typical markets Africa, Asia, LATAM, CIS European Union and PIC/S aligned markets
Inspection depth Moderate Very detailed
Data integrity focus Growing Central requirement
Upgrade investment Lower Significantly higher

How to Choose Your Path

  1. Map your priority export markets for the next three to five years.
  2. Run a gap assessment of your facility against both frameworks.
  3. Estimate the capex and timeline for each upgrade route.
  4. Plan a phased approach, starting with WHO-GMP and building towards EU-GMP where the business case supports it.
Key takeaway

WHO-GMP is the practical gateway to most emerging markets, while EU-GMP positions a facility for regulated markets and premium partnerships. A clear market strategy should drive which certification you pursue first.

Need help assessing your facility? Our regulatory and turnkey teams can carry out a detailed gap analysis and build a realistic upgrade roadmap.

admin

Part of the Zanax Health editorial team, sharing practical insights on pharma regulation, manufacturing and global trade.

Keep Reading

Related Articles

Let's Work Together

Planning a Pharma Project or Looking for a Reliable Supply Partner?

Share your requirement and our specialists will get back within one business day with a clear plan, timeline and quote.